To review the most recent studies assessing the preparedness of healthcare practitioners to provide anti-HIV preexposure prophylaxis (PrEP) and suggest areas for future implementation research.
INTRODUCTION
Over the past five years, several randomized, controlled studies have demonstrated the efficacy of oral antiretroviral preexposure prophylaxis (PrEP) to decrease the transmission of HIV in diverse populations when participants were highly adherent [1-3,4 && , 5, 6] . Based on the results of these studies, the US Food and Drug Administration approved the use of tenofovir-emtricitabine for use as daily PrEP in 2012 [7] ; and in 2014, the US Centers for Disease Control and Prevention (CDC) issued comprehensive guidelines recommending that PrEP be included as a prevention option for individuals at high-risk for HIV acquisition [8 && ]. More recently, demonstration projects in the USA [9 && ], Kenya and Uganda [10 && ], and Brazil [11 && ] have shown that many persons at risk for HIV infection are interested in using PrEP, and many participants are able to take PrEP with high adherence. With encouraging results from these studies and issuance of normative guidelines, for PrEP to have a major public health impact in decreasing HIV incidence, it needs to be provided in primary care settings.
As with any biobehavioral intervention, healthcare professionals will play a critical role in the successful implementation of PrEP. These 'gatekeepers' will need to be informed about the clinical aspects of PrEP management, be willing to prescribe it, trained in its use, and need to be supported with resources to simplify the incorporation of this novel intervention into practice. However, the initial adoption of PrEP by healthcare providers has been slow [12] , suggesting a need to understand providers' attitudes and experiences with PrEP. The review summarizes recent studies assessing providers' usage and intentions regarding prescribing PrEP, with a focus on three interrelated aspects of provider preparedness: awareness of and willingness to prescribe PrEP; challenges with identifying those persons who would benefit from PrEP (i.e., conducting HIV risk assessments) and novel interventions to address and overcome these challenges; and strategies to support the wider appropriate use of PrEP in care settings.
AWARENESS AND WILLINGNESS TO PRESCRIBE PREEXPOSURE PROPHYLAXIS AMONG US PROVIDERS
Many of the recent studies assessing providers' opinions and PrEP experiences have focused on clinicians in the USA, which may be an appropriate starting point given the USA was the first country in which tenofovir-emtricitabine was approved for clinical use as antiretroviral PrEP [13] . Based on surveys conducted in the last 1-2 years, awareness of PrEP appears to be high among United States HIVcare providers, a group of clinicians that might be expected to be among the first to be knowledgeable about PrEP. In a study of 184 providers affiliated with a regional HIV/AIDS educational center in New England, 89% had heard of PrEP (as of 2013), though 25% were not familiar with CDC guidance about PrEP provision that had been issued 2 years before the survey [14 & ]. Few respondents (19%) had prescribed PrEP, though half of those who had not prescribed PrEP believed that they would do so in the future. A survey of 515 HIV-care providers and primary care providers (PCPs) in 10 United States cities (during 2014-2015) found that 97% of HIVcare providers and 76% of PCPs had heard of PrEP, suggesting that awareness was lower among generalist PCPs than HIV specialists [15 & ].
One of the largest studies of provider opinions about PrEP in the USA was a national survey of 573 infectious diseases physicians conducted in June to July 2013. Three-fourths of respondents supported the concept that PrEP should be provided to some patients, but 14% were unsure, and 12% did not support PrEP. Only 9% of physicians had prescribed PrEP, 43% had not provided PrEP, but would be willing to do so, 34% believed PrEP was not relevant to their practice, and 14% would not provide PrEP in the future. Reasons why respondents would not be willing to provide PrEP included concerns about adherence and selection of resistant viral strains (77%), cost and reimbursement issues (57%), the use of potentially toxic drugs in healthy persons (53%), and a perception that insufficient evidence supporting the efficacy of PrEP existed in real-world settings [16 && ]. Overall, the findings of this study highlight that positive attitudes towards PrEP do not necessarily result in actual prescribing experiences or intentions. In addition to theoretical concerns that may cause providers to be cautious about prescribing PrEP, practical barriers could limit prescribing. For example, providers from the New England study cited multiple 'real-world' barriers to prescribing PrEP, including a need for more training, few patient requests for PrEP, concerns about insurance coverage for PrEP, and time constraints, among others [14 & ]. A hypothetical provider 'cascade' for PrEP may be a useful construct to conceptualize the various aspects of preparedness (e.g., awareness, willingness, and training) that must be achieved for different types of providers to implement PrEP (Fig. 1 ).
WHICH PROVIDERS WILL PRESCRIBE PREEXPOSURE PROPHYLAXIS IN THE UNITED STATES?
Qualitative studies with providers conducted in 2012, suggested that a potential barrier to implementing PrEP was a so-called 'purview paradox' among HIV-care providers and PCPs. In this study, many HIV-care providers did not perceive themselves to be well positioned to prescribe PrEP (as some infrequently provided care to HIV-uninfected
KEY POINTS
Healthcare providers are likely to play a critical role in implementation of PrEP in care settings.
Recent studies suggest that specialist providers are aware of PrEP and support its provision as a public health intervention, but that prescribing has been limited to a minority of 'innovators and early adopters'.
Many clinicians are cautious about providing PrEP because of concerns about the efficacy and safety of PrEP; providers also perceive practical barriers to prescribing PrEP in 'real-world' settings.
Comprehensive risk assessments will be necessary to identify those persons who would benefit from PrEP, but risk assessment practices are suboptimal among providers because of lack of training, provider and patient discomfort, and time constraints.
Healthcare practitioners could serve as a valuable asset in the roll out of PrEP, if they are provided with training programs about PrEP and sexual history-taking, novel tools to facilitate routine HIV risk assessments, and opportunities to communicate with trusted colleagues about successful experiences with PrEP. persons), and PCPs believed that prescribing PrEP would not be feasible in their practices (given limited experience prescribing antiretroviral medications) [17 & ]. However, more recent studies suggest that attitudes and practices with PrEP may be evolving among HIV-care providers and PCPs. A follow-up study of infectious diseases physicians in the USA that was conducted in September 2014, several months after the release of CDC guidelines for PrEP, found that one-third of the respondents had prescribed PrEP to sexual partners of their HIV-infected patients. The finding suggested that there may have been an increase in the proportion of physicians who had prescribed PrEP as compared with 1 year previously [18 & ]. However, inferring secular trends in prescribing rates from these two studies must be done with caution, as these studies did not necessarily enroll the same sample of providers. Another encouraging finding from this study was that a majority of HIV-care providers reported beliefs that counseling their HIV-infected patients about PrEP for partners, offering clinical visits to partners, and prescribing PrEP to partners (when indicated), should be part of their clinical role. The survey of HIV-care providers and PCPs in 10 United States cities that was completed in 2015, was also encouraging, in which 90% of HIV-care providers and 80% of PCPs indicated they would be willing to prescribe PrEP [15 & ]. Therefore, both groups of providers may be increasingly open to prescribing PrEP, with the caveat that clinicians who participate in surveys about HIV prevention may be more willing than others to incorporate HIV prevention strategies, such as PrEP, into their practices. In addition to studies of PCPs and HIV-care providers, surveys to assess attitudes and experiences among practitioners who specialize in the diagnosis and treatment of sexually transmitted infections, as well as practitioners at HIV testing sites, will also be needed. These providers are likely to encounter many persons who may benefit from PrEP, and currently, little is known about their opinions and practices regarding PrEP provision.
Importantly, less than half of the providers in the study of infectious diseases physicians indicated that they felt adequately prepared to prescribe PrEP to persons who inject drugs (PWID) [18 & ]. Studies to understand why providers may report different prescribing intentions for patients with specific indications for PrEP, such as PWID, will be important to prevent disparities in access to PrEP. Efforts to ensure equitable prescribing practices may also need to address any implicit behavioral and/or racial biases among clinicians, as a study of medical students detected evidence of implicit biases against racial minorities when making hypothetical prescribing decisions for PrEP [19 & ].
PROVIDERS OUTSIDE OF THE UNITED STATES
As the vast majority of persons at risk for HIV acquisition reside outside the USA, a major consideration for equitable access to PrEP, globally is whether providers in other nations will prescribe PrEP, when PrEP becomes available locally. Currently, few countries have issued normative guidelines for clinicians [ ], may also prompt guidelines in these locations. As clinicians' practices may change in response to guidelines, they could potentially be willing to prescribe PrEP medications without formal approval by regulatory bodies. For example, clinicians routinely prescribe antiretroviral medications for postexposure prophylaxis and prevention of mother-to-child transmission without formal prevention indications. Therefore, Schematic to represent the steps in the continuum of provider knowledge and experience with providing PrEP. This schematic can be applied to the global community of healthcare providers or to specific subgroups of providers with similar geography (e.g., the USA) or professional background (e.g., primary care providers). Heights of bar graphs are hypothetical for the purposes of illustration, given heterogeneity of provider engagement and incomplete data on provider opinions and practices. The arrows represent favorable amplification effects from engaging providers as 'trainers' for their colleagues. PrEP, preexposure prophylaxis. studies to assess provider attitudes towards PrEP in multiple geographic regions, particularly in settings where guidelines are anticipated, are needed.
To address this need, several studies have assessed non-American provider opinions about PrEP. In Peru, 58% of 186 providers (mostly attendees of an HIV conference in 2012) were aware of PrEP, with greater awareness among providers caring for large numbers of men who have sex with men (MSM) [24 & ]. Forty-five percent of providers reported they would be likely to prescribe oral PrEP at the time of the survey, but 60-70% would be likely to prescribe PrEP, if more efficacy data were available or intermittent use were shown to be effective; lack of formal guidelines and concerns about risk compensation were frequently cited concerns. Most (80%) of a heterogeneous sample of 86 Canadian physicians were familiar with PrEP when surveyed in 2012-2013, though less than half were willing to prescribe PrEP [25] .
Consistent with these quantitative surveys, a qualitative study of providers from four cities in the Americas (San Francisco, New York, Lima, and Rio de Janeiro) completed in 2012, identified a theme that providers were 'conflicted' about providing PrEP, as they were eager to enhance HIV prevention for their clients, but were also concerned about diverting resources from HIV treatment [26] . The need to assess provider opinions about PrEP may be particularly important in areas in which resources for HIV treatment are limited, as providers may perceive ethical dilemmas in terms of resource allocation between PrEP and antiretroviral treat-
In addition to assessments among HIV specialists and PCPs, characterizing attitudes among providers who practice in sexual health clinics outside of the USA will be important. These providers might reasonably be expected to be supportive of novel protective interventions for their clients. However, a survey of 328 sexual health practitioners in the United Kingdom suggested that these providers shared similar concerns as providers elsewhere, and only half thought PrEP should be available by
Overall, a consistent theme that has emerged from provider assessments in the USA and in selected international regions, is that many of these stakeholders support PrEP provision as a public health intervention, but residual concerns about negative consequences of PrEP use and practical hurdles may limit prescribing. Moreover, even if providers are informed about PrEP, motivated and trained to prescribe this intervention, and provided with structural supports to overcome practical barriers, an additional consideration is whether frontline clinicians will be able to identify persons who are most likely to benefit from PrEP.
IDENTIFYING THOSE PERSONS WHO WOULD BENEFIT FROM PREEXPOSURE PROPHYLAXIS
Ideally, providers would have the skills, time, and motivation to conduct comprehensive risk assessments as part of routine care for their patients. However, assessments of sexual risk behaviors, sexual orientation, and gender identity, all of which may influence HIV risk, tend to occur infrequently in primary care [ ]. The training was based on the theory of planned behavior (i.e., that personal attitudes, social norms, and self-efficacy, influence intentions and behaviors) and included information about HIV/sexually transmitted infection (STI) epidemiology, and role-modeling and/or role-playing of effective techniques. The promising pilot study suggests that scale-up of brief, theory-based, interactive trainings for providers could improve risk assessments. In a qualitative study of medical students, participants voiced a need for patient interviews and clinical scenarios focused on sexual health discussions with MSM to improve their comfort with risk assessment for this important population [31 & ]. A survey of 1394 MSM who engaged in online sexual networking and reported interest in using PrEP, found that 42% were not comfortable discussing same-sex behaviors with their PCPs, many had never discussed anal sex behaviors or PrEP with PCPs, and three-fourths believed that their PCP would not be willing to prescribe PrEP [32] . Therefore, trainings that emphasize culturally-sensitive and nonjudgmental approaches to history-taking could be critical to ensure PrEP uptake in primary care. Medical educators and professional organizations for PCPs should be informed about the results of these studies and encouraged to expand communication curricula about sexual health.
In addition to skills-based trainings, several novel approaches to help providers identify those persons who would benefit from PrEP are under development. Risk prediction tools for clinical use have been developed for MSM [33 & ] and PWID [34 & ]. With these point-of-care tools, responses to several questions about specific patient-reported behaviors are used to generate individualized estimates of HIV risk in real-time. Clinicians can record patients' responses to questions during in-person interviews, or patients can enter responses directly into the tool before clinic visits (e.g., in waiting rooms). The use of prediction tools may result in more accurate risk assessments than clinician judgment in some cases, which could optimize PrEP prescribing decisions. However, these tools have greater sensitivity than specificity, suggesting that they will be most helpful as screening tools for PrEP. For individuals who have positive screening results, providers would still need to be skilled in detailed risk assessments to make optimal recommendations about PrEP, so these tools are likely to be most helpful when paired with skills-based trainings. A pilot study found that the use of a risk prediction tool for MSM on a computer tablet in a clinic waiting room ('iPad-based risk assessment') was generally acceptable to patients in two United States cities, though provider opinions about this approach were not assessed [35 & ]. Patients may be more likely to accurately disclose sensitive information during computerbased interviews than during personal interviews with providers [36], and tablet-based behavioral assessments have been successfully utilized with HIV-infected patients and other cohorts [37]; therefore, additional studies with routine tablet-based assessments in primary care are warranted.
Automated, individualized risk assessments based on the data routinely embedded in patients' electronic health records (EHRs) offers another promising strategy to identify individuals who may benefit from PrEP. With this approach, the rich array of data available in EHRs is used to determine the EHR profile of patients at high-risk of acquiring HIV. Automated algorithms are then developed that can risk-stratify individuals based on their EHR profiles, and these algorithms can be programmed to deliver real-time alerts to clinicians when patients who might benefit from PrEP are identified. Similar algorithms have been successfully developed for the detection and reporting of other STIs in care settings [38] . If EHR-based algorithms demonstrate acceptable performance for PrEP, they could provide a potentially scalable, generalizable, and automated approach to facilitate risk assessments in primary care settings. As with other risk-prediction tools, these algorithms may not be sufficiently sensitive or specific to replace clinician interviews. If these tools can increase the frequency and accuracy of risk assessment, however, they could complement efforts to train clinicians in sexual history-taking.
SUPPORTING THE DIFFUSION OF INNOVATION FOR PREEXPOSURE PROPHYLAXIS
Diffusion of innovation theory describes the factors that influence the adoption of novel technologies by a population of end-users, including medical interventions by clinicians or patients [39] . This theory provides a useful framework for charting the trajectory of PrEP uptake in care settings. The temporal uptake of innovations tends to follow an Sshaped curve, with early use limited to a small proportion of the total population, innovators (2.5% of all providers) and early adopters (13.5%), with subsequent expansion to early (34%) and late (34%) majorities, and finally adoption by traditionalists, or 'laggards' (16%) [40] (Fig. 2) . Importantly, widespread adoption of innovations is uncertain during the early stages of diffusion, prior to attainment of an inflection point in adoption. Clinician assessments suggest that PrEP uptake has been limited to innovators and early adopters in the USA and only small groups of innovators elsewhere. Therefore, the diffusion of PrEP appears to be at a critical stage, such that engagement of a larger group of early providers will be needed to achieve widespread adoption of PrEP. Of note, the stages of diffusion may not always follow a classic S-shaped curve in healthcare systems where the introduction of new interventions is typically universal, as occurs in some public healthcare systems.
The diffusion of innovation framework suggests interventions that may facilitate adoption of PrEP. One of the most important strategies is to invest in innovators and early adopters and to promote the visibility of successful early adopter activities [40] . In the USA, some clinical sites have reported early successes with PrEP provision, including three settings in San Francisco (a private health maintenance organization, an HIV-specific reproductive health program, and a demonstration project at the municipal STI clinic) [41 && ] and a community health center in Boston that specializes in the care of sexual and gender minorities [42] . Clinicians at this health center have prescribed PrEP to over 600 patients in total with generally positive experiences, demonstrating that PrEP provision is feasible in primary care [42] . Educational programs that summarize these positive experiences for their generalist colleagues could promote uptake by the 'early majority' of providers, and are being rolled out in several jurisdictions, most notably New York City and State [43] . Peer-to-peer social interactions (sometimes over food, using Grand Rounds or case conference formats) between familiar colleagues are also thought to be critical for widespread adoption. When possible, local champions should also be identified and supported (e.g., with time and funding) so they can 'lead by example' [40] and inspire others toward change.
Finally, practitioners must be provided with accurate data on the efficacy and safety data for PrEP, so that frequently-cited concerns about the risk-benefit ratio of PrEP are directly addressed. After the completion of multiple efficacy studies and several demonstration projects, an abundance of data suggest that PrEP is highly protective when taken regularly and is generally safe, even though longer-term safety data are needed. 
CONCLUSION
Over the past 5 years, successful PrEP efficacy studies and demonstration projects suggest that PrEP deployment may help decrease HIV incidence globally, particularly when coupled with offering treatment to all people living with HIV [46, 47] . However, the increase in the number of PrEP prescribers may continue to be gradual, given a need to enhance numerous aspects of the provider 'PrEP cascade' to achieve widespread prescribing. If governments, researchers, and medical educators are willing to commit sufficient resources to train providers, and to develop innovative approaches to HIV risk assessments that can foster the diffusion of PrEP into care settings, then healthcare practitioners could play an important role in promoting wider PrEP use.
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